Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: A review

Journal of Neuro-Oncology

Volumn 104, Issue 3, 2011, Pages 639-646

  Henriksson, Roger ^a,b   Asklund, Thomas ^a   Poulsen, Hans Skovgaard ^b,c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c FINSEN LABORATORY   (Denmark)

Author keywords

Bevacizumab; Glioblastoma multiforme; Quality of life

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CORTICOSTEROID; DEXAMETHASONE; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COGNITION; COGNITIVE DEFECT; COMMUNICATION DISORDER; CORRELATIONAL STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DROWSINESS; DRUG COMPETITION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HAIR LOSS; HUMAN; MOTOR DYSFUNCTION; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION INJURY; REVIEW; SEIZURE; SOMNOLENCE; SYSTEMATIC REVIEW;

BRAIN NEOPLASMS; COGNITION DISORDERS; GLIOBLASTOMA; HUMANS; QUALITY OF LIFE; STATISTICS AS TOPIC; TIME FACTORS;

EID: 80052634162     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0565-x     Document Type: Review

References (83)

1. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK (2007) WHO classication of tumours of the central nervous system. IARC, Lyon
2. DN Louis H Ohgaki OD Wiestler, et al. 2007 The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 97 109 17618441 10.1007/s00401-007-0243-4 (Pubitemid 47103521)
3. Garside R, Pitt M, Anderson R et al (2007) The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 11:iii-iv, ix-221
4. JG Gurney N Kadan-Lottick 2001 Brain and other central nervous system tumors: rates, trends, and epidemiology Curr Opin Oncol 13 160 166 11307058 10.1097/00001622-200105000-00005 1:STN:280:DC%2BD3Mzot12lsA%3D%3D (Pubitemid 32433971)
5. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
6. R Stupp ME Hegi WP Mason, et al. 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 19269895 10.1016/S1470-2045(09)70025-7 1:CAS:528:DC%2BD1MXlsVKhs74%3D
7. ET Wong KR Hess MJ Gleason, et al. 1999 Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572 2578 10561324 1:STN:280:DC%2BD3c%2FjtVSmsQ%3D%3D (Pubitemid 29368260)
8. KV Ballman JC Buckner PD Brown, et al. 2007 The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Neuro Oncol 9 29 38 17108063 10.1215/15228517-2006-025 1:CAS:528:DC%2BD2sXht1Ojs7w%3D (Pubitemid 46543486)
9. Fine HA, Puduvalli VK, Chamberlain MC et al (2008) Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): a phase III study. J Clin Oncol 26(suppl; abstr 2005)
10. KR Lamborn WK Yung SM Chang, et al. 2008 Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas Neuro Oncol 10 162 170 18356283 10.1215/15228517-2007-062
11. DR Macdonald G Kiebert M Prados A Yung J Olson 2005 Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life Cancer Invest 23 138 144 15813507 1:CAS:528:DC%2BD2MXjvVyktrc%3D (Pubitemid 40463912)
12. C Meyers C Boake 1993 Neurobehavioral disorders experienced by brain tumor patients: rehabilitation strategies Cancer Bull 45 362 364 (Pubitemid 23262154)
13. CA Meyers 1986 Neuropyschologic deficits in brain-tumour patients: effects of location, chronicity, and treatment Cancer Bull 38 20 32
14. CA Meyers RS Scheibel 1990 Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment Oncology (Williston Park) 4 115 122 1:STN:280:DyaK3czlvFOntQ%3D%3D (Pubitemid 20251543)
15. MJ Taphoorn M Klein 2004 Cognitive deficits in adult patients with brain tumours Lancet Neurol 3 159 168 14980531 10.1016/S1474-4422(04)00680-5 (Pubitemid 38229950)
16. I Bosma MJ Vos JJ Heimans, et al. 2007 The course of neurocognitive functioning in high-grade glioma patients Neuro Oncol 9 53 62 17018697 10.1215/15228517-2006-012 (Pubitemid 46543489)
17. JX Cheng X Zhang BL Liu 2009 Health-related quality of life in patients with high-grade glioma Neuro Oncol 11 41 50 18628405 10.1215/15228517-2008-050
18. AR Giovagnoli A Silvani E Colombo A Boiardi 2005 Facets and determinants of quality of life in patients with recurrent high grade glioma J Neurol Neurosurg Psychiatry 76 562 568 15774446 10.1136/jnnp.2004.036186 1:STN:280:DC%2BD2M7ktlektg%3D%3D (Pubitemid 40486584)
19. D Khuntia P Brown J Li MP Mehta 2006 Whole-brain radiotherapy in the management of brain metastasis J Clin Oncol 24 1295 1304 16525185 10.1200/JCO.2005.04.6185 1:CAS:528:DC%2BD28XjtlGhtrg%3D (Pubitemid 46622033)
20. J Li SM Bentzen J Li, et al. 2008 Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis Int J Radiat Oncol Biol Phys 71 64 70 18406884 10.1016/j.ijrobp.2007.09.059 (Pubitemid 351506468)
21. JJ Heimans J Martin B Taphoorn 2002 Impact of brain tumour treatment on quality of life J Neurol 249 955 960 12195437 10.1007/s00415-002-0839-5 (Pubitemid 35002212)
22. DE Fujii AM Wylie 2003 Neurocognition and community outcome in schizophrenia: long-term predictive validity Schizophr Res 59 219 223 12414078 10.1016/S0920-9964(01)00328-0 (Pubitemid 35284695)
23. Stong C (2003) Can neurocognition predict future quality of life in patients with mental illness? http://www.neuropsychiatryreviews.com/mar03/mar03- neurocognition.html. Accessed 5 May 2009
24. DE Fujii AM Wylie JH Nathan 2004 Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness Schizophr Res 69 67 73 15145472 10.1016/S0920-9964(03)00122-1 (Pubitemid 38625760)
25. W Roa Pm Brasher G Bauman, et al. 2004 Abbreviation course of radiation therap in lder patients with glioblastoma multiforme: a prospective randomized clinical trial J Clin Oncol 22 1582 1588 10.1200/JCO.2004.06.082 (Pubitemid 41079795)
26. M Walker J Brown K Brown, et al. 2003 Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma J Neurooncol 63 179 186 12825822 10.1023/A:1023900802254 1:STN:280:DC%2BD3s3pvVWntg%3D%3D (Pubitemid 36705687)
27. DD Correa 2010 Neurocognitive function in brain tumors Curr Neurol Neurosci Rep 10 232 239 20425039 10.1007/s11910-010-0108-4
28. M Klein JJ Heimans NK Aaronson, et al. 2002 Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study Lancet 360 1361 1388 12423981 10.1016/S0140-6736(02)11398-5 1:STN:280:DC%2BD38nmsVWmsg%3D%3D (Pubitemid 35341299)
29. M Klein NH Engelberts HM van der Ploeg, et al. 2003 Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life Ann Neurol 54 514 520 14520665 10.1002/ana.10712 (Pubitemid 37176548)
30. MJ Taphoorn 2003 Neurocognitive sequelae in the treatment of low-grade gliomas Semin Oncol 30 6 Suppl 19 45 48 14765385 10.1053/j.seminoncol.2003.11. 023 (Pubitemid 38199164)
31. M Klein MJ Taphoorn JJ Heimans, et al. 2001 Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients J Clin Oncol 19 4037 4047 11600605 1:STN:280:DC%2BD3MrlsVShtA%3D%3D (Pubitemid 32976690)
32. SJ Lupien CJ Gillin RL Hauger 1999 Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans Behav Neurosci 113 420 430 10443770 10.1037/0735-7044.113.3.420 1:CAS:528:DyaK1MXltFOqu7w%3D (Pubitemid 29340055)
33. AH Young BJ Sahakian TW Robbins PJ Cowen 1999 The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers Psychopharmacology (Berl) 145 260 266 10.1007/s002130051057 1:CAS:528:DyaK1MXlvFChtr0%3D (Pubitemid 29393475)
34. MA de Vries RR van Litsenburg J Huisman, et al. 2008 Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study Health Qual Life Outcomes 6 103 19036151 10.1186/1477-7525-6-103
35. C Hempen E Weiss CF Hess 2002 Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10 322 328 12029432 10.1007/s00520-001-0333-0 (Pubitemid 36056287)
36. A Sturdza BA Millar N Bana, et al. 2008 The use and toxicity of steroids in the management of patients with brain metastases Support Care Cancer 16 1041 1048 18256860 10.1007/s00520-007-0395-8
37. MJ Taphoorn R Stupp C Coens, et al. 2005 Health-related quality of life in patients with glioblastoma: a randomised controlled trial Lancet Oncol 6 937 944 16321761 10.1016/S1470-2045(05)70432-0 (Pubitemid 41685226)
38. D Osoba M Brada WK Yung M Prados 2000 Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme J Clin Oncol 18 1481 1491 10735896 1:CAS:528: DC%2BD3cXivVeis74%3D (Pubitemid 30205394)
39. WK Yung RE Albright J Olson, et al. 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 588 593 10944597 10.1054/bjoc.2000.1316 1:CAS:528: DC%2BD3cXmvVCgsrs%3D (Pubitemid 30636298)
40. M Brada K Hoang-Xuan R Rampling, et al. 2001 Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse Ann Oncol 12 259 266 11300335 10.1023/A:1008382516636 1:STN:280: DC%2BD3M3gvFamtg%3D%3D (Pubitemid 32223879)
41. Hart MG, Grant R, Garside R et al (2008) Temozolomide for high grade glioma. Cochrane Database Syst Rev 4:CD007415
42. MJ Taphoorn MJ van den Bent ME Mauer, et al. 2007 Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial J Clin Oncol 25 5723 5730 18089866 10.1200/JCO.2007.12.7514
43. Wang M, Cairncross G, Shaw E et al (2009) Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. J Clin Oncol 27(suppl; abstr e20519)
44. BW Corn M Wang S Fox, et al. 2009 Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03 J Neurooncol 95 247 257 19533025 10.1007/s11060-009-9923-3
45. T Trojanowski J Peszyński K Turowski, et al. 1989 Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy J Neurosurg 70 18 23 2642546 10.3171/jns.1989.70.1.0018 1:STN:280:DyaL1M%2FotVygsQ%3D%3D
46. Hart MG, Grant R, Garside R et al (2008) Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev 3:CD007294
47. JC Yang L Haworth RM Sherry, et al. 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 12890841 10.1056/NEJMoa021491 1:CAS:528:DC%2BD3sXms1Klu7w%3D (Pubitemid 36910021)
48. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528: DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
49. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
50. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
51. V Stark-Vance 2005 Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma Neuro Oncol 7 369 (abstr 342)
52. Raval S, Hwang S, Dorsett L (2007) Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). J Clin Oncol 25(suppl; abstr 2078)
53. JJ Vredenburgh A Desjardins JE Herndon 2nd, et al. 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4729 17947719 10.1200/JCO.2007.12.2440 1:CAS:528:DC%2BD2sXhtlCgsLjF (Pubitemid 350086473)
54. JJ Vredenburgh A Desjardins JE Herndon 2nd, et al. 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259 17317837 10.1158/1078-0432.CCR-06-2309 1:CAS:528:DC%2BD2sXhvF2htr8%3D (Pubitemid 46424067)
55. SA Ali WM McHayleh A Ahmad, et al. 2008 Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases J Neurosurg 109 268 272 18671639 10.3171/JNS/2008/109/8/0268 1:CAS:528:DC%2BD1cXhtVSktb7E
56. F Bokstein S Shpigel DT Blumenthal 2008 Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors Cancer 112 2267 2273 18327820 10.1002/cncr.23401 1:CAS:528:DC%2BD1cXmt1CnsL8%3D (Pubitemid 351628638)
57. Cloughesy TF, Prados MD, Wen PY et al (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26(suppl; abstr 2010b)
58. A Desjardins DA Reardon JE Herndon 2nd, et al. 2008 Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas Clin Cancer Res 14 7068 7073 18981004 10.1158/1078-0432.CCR-08-0260 1:CAS:528:DC%2BD1cXhtlens7fJ
59. S Guiu S Taillibert O Chinot, et al. 2008 Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study Rev Neurol (Paris) 164 588 594 1:STN:280: DC%2BD1cvotl2ntA%3D%3D (Pubitemid 351902232)
60. AD Norden GS Young K Satayesh, et al. 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787 18316689 10.1212/01.wnl.0000304121.57857.38 1:CAS:528: DC%2BD1cXitlyqs7o%3D
61. HS Friedman MD Prados PY Wen, et al. 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733 4740 19720927 10.1200/JCO.2008.19.8721 1:CAS:528:DC%2BD1MXhtlGgtbbM
62. Gilbert MR, Wang M, Aldape K et al (2009) RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J Clin Oncol 27(suppl; abstr 2011)
63. PL Nghiemphu W Liu Y Lee, et al. 2009 Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience Neurology 72 1217 1222 19349600 10.1212/01.wnl.0000345668.03039.90 1:CAS:528:DC%2BD1MXjslKrsrs%3D
64. HS Poulsen K Grunnet M Sorensen, et al. 2009 Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours Acta Oncol 48 52 58 19031176 10.1080/02841860802537924 1:CAS:528: DC%2BD1cXhsFagtbjJ
65. RM Zuniga R Torcuator R Jain, et al. 2009 Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan J Neurooncol 91 329 336 18953493 10.1007/s11060-008-9718-y 1:CAS:528:DC%2BD1MXjvFemtQ%3D%3D
66. Cloughesy T, Vredenburgh JJ, Day B et al (2010) Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol 28(suppl; abstr 2008)
67. Desjardins A, Vredenburgh JJ, Reardon DA et al (2010) Long-term survival from the initial trial of bevacizumab and irinotecan. J Clin Oncol 28(suppl; abstr 2045)
68. Reardon D, Desjardins A, Vredenburgh JJ et al (2009) Bevacizumab plus etoposide among recurrent malignant glioma patients: phase II study final results. J Clin Oncol 27(suppl; abstr 2046)
69. Soffietti R, Rudà R, Trevisan E et al (2009) Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: A multicenter Italian study. J Clin Oncol 27(suppl; abstr 2012)
70. Trevisan E, Picco E, Rudà R et al (2009) Salvage therapy with bevacizumab and fotemustine in recurrent high grade glioma. Eur J Can Suppl 7:499(abstr P-8719)
71. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al (2010) Phase II study of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: final results. J Clin Oncol 28(suppl; abstr 2055)
72. PH Gutin FM Iwamoto K Beal, et al. 2009 Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas Int J Radiat Oncol Biol Phys 13 1200 1206
73. TN Kreisl L Kim K Moore, et al. 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 740 745 19114704 10.1200/JCO.2008.16.3055 1:CAS:528:DC%2BD1MXjsVCjs7o%3D
74. Raizer JJ, Grimm S, Rice L et al (2009) A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas. J Clin Oncol 27(suppl; abstr 2044)
75. A Lai E Filka B McGibbon, et al. 2008 Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability Int J Radiat Oncol Biol Phys 71 1372 1380 18355978 10.1016/j.ijrobp.2007.11.068 1:CAS:528:DC%2BD1cXoslWqsLo%3D
76. Gruber ML, Raza S, Gruber D et al (2009) Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity. J Clin Oncol 27(suppl; abstr 2017)
77. Nicholas MK, Lucas RV, Arzbaecher J et al (2009) Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: preliminary results of a phase II study. J Clin Oncol 27(suppl; abstr 2016)
78. Vredenburgh JJ, Desjardins A, Reardon DA et al (2010) Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 28(suppl; abstr 2023)
79. Omuro AM, Beal K, Karimi S et al (2010) Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). J Clin Oncol 28(suppl; abstr 2036)
80. Vredenburgh JJ, Wefel J, Coughesy T et al (2009) Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Eur J Cancer Suppl 7:495(abstr O-8701)
81. Wefel JS, Cloughesy T, Zazzali J et al (2009) Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study. J Clin Oncol 27(suppl; abstr 2056)
82. Green RM, Woyshner EA, Nghiemphu L et al (2010) Use of bevacizumab to faciliate up-front chemoradiation in poor-risk patients with glioblastoma multiforme by improving neurologic function. J Clin Oncol 28(suppl; abstr 2059)
83. TT Batchelor DG Duda E di Tomaso, et al. 2010 Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 28 2817 2823 20458050 10.1200/JCO.2009.26.3988 1:CAS:528:DC%2BC3cXptFKmu78%3D